Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Share-based Compensation: 2012-2025

Historic Share-based Compensation for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $4.1 million.

  • CorMedix's Share-based Compensation rose 231.21% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 128.58%. This contributed to the annual value of $6.1 million for FY2024, which is 11.57% up from last year.
  • CorMedix's Share-based Compensation amounted to $4.1 million in Q3 2025, which was up 51.86% from $2.7 million recorded in Q2 2025.
  • CorMedix's 5-year Share-based Compensation high stood at $4.1 million for Q3 2025, and its period low was $50,000 during Q2 2022.
  • In the last 3 years, CorMedix's Share-based Compensation had a median value of $2.2 million in 2023 and averaged $2.1 million.
  • As far as peak fluctuations go, CorMedix's Share-based Compensation slumped by 95.05% in 2022, and later spiked by 1,758.60% in 2024.
  • Over the past 5 years, CorMedix's Share-based Compensation (Quarterly) stood at $1.3 million in 2021, then slumped by 30.26% to $874,051 in 2022, then spiked by 36.00% to $68,000 in 2023, then surged by 1,758.60% to $1.2 million in 2024, then soared by 231.21% to $4.1 million in 2025.
  • Its Share-based Compensation was $4.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and $3.5 million in Q1 2025.